# US 12,215,136 B2 · Exosome for stimulating T cell and pharmaceutical use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,215,136 B2
- Document ID: US12215136B2
- Status: Granted
- Kind: B2
- Application number: 18/295,631
- Filed: 2023-04-04
- Published: 2023-09-14
- Granted: 2025-02-04
- Earliest claimed: 2016-12-02
- Assignees: The Catholic University of Korea Industry-Academic Cooperation Foundation
- Applicants: The Catholic University of Korea Industry-Academic Cooperation Foundation
- Inventors: Tai Gyu Kim; Hyun Jung Sohn; Su Eon Kim
- Web page: https://patentgrep.com/patent/US12215136B2

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4243: {Wilms tumor 1 [WT1]}
- A61K 40/4272: {Melan-A/MART}
- A61K 40/46: Viral antigens
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 15/86: Viral vectors
- C12N 2501/25: Tumour necrosing factors [TNF]
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/599: with CD designations not provided for elsewhere
- C12N 2502/1121: Dendritic cells
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.

## Claims

### Claim 1

An exosome which expresses a human leukocyte antigen (HLA), CD32, CD80, CD83, and 4-1BBL.

### Claim 2 (depends on 1)

The exosome of claim 1, wherein the exosome is derived from artificial antigen-presenting cells prepared by introducing nucleic acids encoding HLA, CD32, CD80, CD83, and 4-1BBL into cells which do not express HLA Class I and II molecules.

### Claim 3 (depends on 2)

The exosome of claim 2, wherein the cells which do not express HLA Class I and II molecules are any one of K562 cells and modified 293T cells.

### Claim 4 (depends on 2)

The exosome of claim 2, wherein the nucleic acid is inserted into a viral vector and delivered into cells.

### Claim 5 (depends on 2)

The exosome of claim 2, wherein the nucleic acid encoding HLA is as set forth in SEQ ID NO: 1.

### Claim 6 (depends on 2)

The exosome of claim 2, wherein the nucleic acid encoding CD80 is as set forth in SEQ ID NO: 2.

### Claim 7 (depends on 2)

The exosome of claim 2, wherein the nucleic acid encoding CD83 is as set forth in SEQ ID NO: 3.

### Claim 8 (depends on 2)

The exosome of claim 2, wherein the nucleic acid encoding 4-1BBL is as set forth in SEQ ID NO: 4.

### Claim 9 (depends on 1)

The exosome of claim 1, wherein the exosome further expresses one or more selected from the group consisting of CD40L, CD70, and OX40L.

### Claim 10 (depends on 1)

The exosome of claim 1, wherein the exosome is sensitized with one or more antigens selected from the group consisting of a tumor antigen, a pathogen antigen, and an autoantibody.